Nirogacestat
Ogsiveo (nirogacestat) is a small molecule pharmaceutical. Nirogacestat was first approved as Ogsiveo on 2023-11-27. It is used to treat aggressive fibromatosis in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Ogsiveo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nirogacestat hydrobromide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| OGSIVEO | SpringWorks Therapeutics | N-217677 RX | 2023-11-27 | 3 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ogsiveo | New Drug Application | 2024-04-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| aggressive fibromatosis | — | D018222 | D48.11 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
NIROGACESTAT HYDROBROMIDE, OGSIVEO, SPRINGWORKS | |||
| 2030-11-27 | ODE-452 | ||
| 2028-11-27 | NCE | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Nirogacestat Hydrobromide, Ogsiveo, Springworks | |||
| 11872211 | 2043-05-19 | U-3754 | |
| 11807611 | 2042-09-08 | DP | U-3754 |
| 11844780 | 2042-09-08 | DP | U-3754 |
| 11504354 | 2042-07-08 | DP | |
| 11612588 | 2042-07-08 | DP | U-3754 |
| 10590087 | 2039-08-09 | DP | |
| 10710966 | 2039-08-09 | DP | U-3754 |
| 10941118 | 2039-08-09 | DP | U-3754 |
| 11820748 | 2039-08-09 | DP | |
| 11845732 | 2039-08-09 | DP | U-3754 |
| 11884634 | 2039-08-09 | DP | |
| 11884635 | 2039-08-09 | DP | |
| 11905255 | 2039-08-09 | DP | |
| 7342118 | 2025-08-18 | DP | |
| 7795447 | 2025-08-18 | DP | |
| 7951958 | 2025-03-11 | DP | |
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aggressive fibromatosis | D018222 | — | D48.11 | — | 4 | 1 | — | 2 | 7 |
| Fibroma | D005350 | — | M72.9 | — | 2 | 1 | — | — | 3 |
| Aggression | D000374 | EFO_0003015 | — | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 8 | 3 | — | — | — | 9 |
| Plasma cell neoplasms | D054219 | — | — | 8 | 3 | — | — | — | 9 |
| Neoplasms | D009369 | — | C80 | 2 | 3 | — | — | 2 | 6 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | — | — | — | 3 |
| Triple negative breast neoplasms | D064726 | — | — | — | 2 | — | — | — | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
| Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
| Kaposi sarcoma | D012514 | — | C46 | — | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Neoplasms by histologic type | D009370 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nirogacestat |
| INN | nirogacestat |
| Description | Nirogacestat is a member of the class of imidazoles that is 1H-imidazole substituted by a 1-[(2,2-dimethylpropyl)amino]-2-methylpropan-2-yl group at position 1 and a {N-[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-L-norvalyl}amino group at position 4. It is a gamma-secretase inhibitor whose hydrobromide salt is indicated for adult patients with progressing desmoid tumours who require systemic treatment. It has a role as an antineoplastic agent and a gamma-secretase modulator. It is a member of tetralins, an organofluorine compound, a secondary carboxamide, a secondary amino compound and a member of imidazoles. It is a conjugate base of a nirogacestat(2+). |
| Classification | Small molecule |
| Drug class | enzyme inhibitors: gamma secretase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(C(C)(C)CNCC(C)(C)C)cn1 |
Identifiers
| PDB | — |
| CAS-ID | 1290543-63-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1770916 |
| ChEBI ID | — |
| PubChem CID | 46224413 |
| DrugBank | DB12005 |
| UNII ID | QZ62892OFJ (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Ogsiveo – SpringWorks Therapeutics
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 813 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
245 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use